Methodological characteristics of Peruvian clinical practice guidelines, 2018 – 2023: A scoping review Authors: Ana Brañez-Condorena, Blanca Solis-Chimoy, Jhonatan R. Mejia, Lesly Chávez-Rimache, David R. Soriano-Moreno, Jose Ernesto Fernández-Chinguel, Alvaro Taype-Rondan, Alexis Carrasco, Alexis Carrasco, César Cayo-Rojas, Saravana Kumar, Saravana Kumar Published: 2025 ABSTRACT BackgroundClinical practice guidelines (CPGs) must be developed through a rigorous and transparent methodology to ensure the appropriateness and reliability of their recommendations. In Peru, little is known regarding how CPGs adhere to established methodological standards.ObjectiveTo describe the methodological characteristics of CPGs developed and published in Peru between 2018 and 2023.MethodsWe conducted a scoping review and searched CPGs on Google, Google Scholar, and relevant local organizational websites. To be included, CPGs had to self-identify as such, have full-text versions available online, provide explicit methodological descriptions, and base their recommendations on systematic reviews, with publication dates between January 2018 and December 2023. We presented the results descriptively and analyzed the methodological differences among CPGs from different organizations using Fisher’s exact tests.ResultsOut of 312 records assessed, 88 CPGs met the inclusion criteria. We found a declining publication trend over the study period: 39 CPGs were published in 2018–2019, 30 in 2020–2021, and 19 in 2022–2023. Most CPGs (60.2%) were developed by the Peruvian Social Security Health Insurance (EsSalud). Oncology was the most prevalent specialty of the CPGs (20.5%) and most CPGs (96.6%) included disease management. 23.7% of CPGs used ≥ 3 search engines, and 76.3% showed the risk of bias assessment. Although most CPGs indicated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology (94.3%), 30.7% missed Summary of Findings tables, 38.6% did not include Evidence-to-Decision frameworks, and only 5.7% used minimal important difference for at least one question. Additionally, economic analyses were infrequently sought or included.ConclusionsThis study highlights significant methodological deficiencies in Peruvian CPGs, including inadequate reporting of search strategies, bias assessments, and key GRADE components. Addressing these shortcomings is crucial for enhancing the quality and reliability of CPGs and promoting equitable healthcare delivery in Peru. Introduction Evidence-based clinical practice guidelines (CPGs) are defined by the Institute of Medicine as “statements that include recommendations, intended to optimize patient care, informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options” [1]. To ensure these recommendations are optimal, CPGs must be developed using a rigorous, transparent, and effective methodology [2,3]. A trustworthy CPG adheres to these standards that emphasize key components, including clearly defined clinical questions, systematic literature searches, the use of a grading system for evidence, explicit criteria for formulating recommendations, external review, and a structured process for updates [1,2]. Local CPGs, developed by countries, health insurance entities, or hospitals, provide valuable context-specific recommendations by considering context-dependent factors such as costs, feasibility, equity, and acceptability. However, previous studies evaluating local CPGs in Latin American countries, including Brazil [4], Mexico [5], and Chile [6], have identified significant methodological deficiencies. Common shortcomings include unclear processes for formulating recommendations [4–6], inadequate systematic searches and selection criteria [4,5], limited consideration of evidence strengths and limitations [4–6], and failure to incorporate patients’ preferences [4,6]. In Peru, an evaluation of 17 CPGs published by the Ministry of Health between 2009 and 2014 revealed similar deficiencies [7], including a lack of information about the guideline development team, minimal use of evidence, and unclear recommendation processes [7]. A further study of 31 CPGs developed by the Peruvian Social Health Insurance System (EsSalud) up to December 2015 reported gaps in evidence-based frameworks and inconsistent reporting of recommendations [8]. In response, the Peruvian Ministry of Health published a technical document in 2015 standardizing CPG methodology, which is mandatory in the public sector and recommended for the private sector. This document stipulated that CPGs should formulate clinical questions and conduct systematic searches to answer them. It also mandated the use of the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) methodology to assess the certainty of the evidence, create Summary of Findings (SoF) tables, and formulate strong or conditional recommendations [9]. Despite the existence of this standard, CPG development in Peru remains decentralized. Different institutions, even within the same sector, develop CPGs independently, with distinct methodological teams and varying capacities. This institutional heterogeneity can influence the methodological quality and consistency of CPGs across the country. Internationally, institutions such as the World Health Organization (WHO) [10], National Institute for Health and Care Excellence (NICE) in the UK [11], and regional organizations such as the Ministry of Health of Argentina [12] and Chile [13] follow rigorous methodologies emphasizing transparency, evidence quality assessment, and regular updates. While Peru’s standards have advanced, they could benefit from greater alignment with these international practices, ensuring guidelines remain evidence-based and relevant. No studies have evaluated whether Peruvian CPGs published after the release of this technical document comply with the globally standardized methodological characteristics required by national regulations. Therefore, we conducted this study to describe the methodological characteristics of the CPGs developed in Peru and published between 2018 and 2023. Materials and methods We performed a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Scoping Reviews (PRISMA-ScR) guidelines [14]. Eligibility criteria We included CPGs developed by public or private organizations in Peru that fulfilled the following criteria: 1) Documents self-named as CPGs, 2) CPGs with full-text versions publicly available online, 3) CPGs that explained -at least briefly- the methodology followed for its development, 4) CPGs that provided recommendations and indicated that these recommendations were based on systematic reviews (SRs), and 5) CPGs published between January 2018 and December 2023 (when the CPG did not present a publication date, the approval resolution date was considered). We included Peruvian CPGs that reported basing their recommendations on SRs, an essential component of evidence-based CPG development. This approach allowed us to focus on CPGs with an evidence-based intent and assess whether they incorporated key methodological components aligned with international standards [10–13] and the national regulations for CPG development in Peru [9]. CPGs that reported only partial updates (revisions and modifications of specific sections to incorporate new evidence, recommendations update, minor methodologies adjusts, or reflect regulatory changes without a full overhaul) were excluded. No restriction was applied regarding the level of healthcare (primary, secondary, or tertiary) for which the CPGs were intended. Search and selection of CPG Two authors (ABC and BSC) independently searched for CPGs on Google and Google Scholar, and the websites of local organizations likely to develop CPGs (S1 Table). Regarding Google and Google Scholar, CPGs were searched until the results yielded at least 100 consecutive entries that did not meet the predefined search criteria. If CPGs from other local organizations were found through Google and Google Scholar, additional searches for other CPGs were conducted on the websites of those organizations. The search was performed on March 22, 2024. Duplicate CPGs were removed manually. Two authors (ABC and BSC) independently selected the CPGs that met the eligibility criteria for inclusion. In case of discrepancies, a third investigator (ATR) was consulted. Data extraction When a CPG was found, all its versions and documents (short version, summarized version, article version, full-text, supplementary material, and others) were searched on Google and the website of the organization responsible for its development. A pilot study was conducted to standardize the data extraction process. Subsequently, six investigators (ABC, BSC, JRM, DRSM, LCR, JEFC) worked in pairs to independently extract the variables of interest using a standardized Microsoft Excel sheet. In case of disagreements, consensus was reached through discussion among the investigators, followed by a second review of the data from the included CPGs to identify the precise information. To ensure the quality of the data collection process, a predefined set of criteria was applied to each variable. This included cross-checking the extracted information with the original documents, verifying consistency across multiple versions and journal articles of the CPGs, and ensuring the accuracy of all recorded data. If consensus could not be reached, another researcher (ATR) was consulted to resolve any uncertainties or clarify discrepancies in the data. Variables of interest included the year of publication, covered area, developing organization (given that Peruvian health institutions operate with distinct processes and capacities), type of CPG (“de novo”, adapted, or adopted), funding sources, targeted population, type and number of authors, patient flowchart report, questions, and table of recommendations report, type of recommendations, authors’ conflict of interest statement, presence of external reviewers, article version, number of search engines, search strategies report, risk of bias assessment, use of a minimally important difference (MID), use of the GRADE methodology, SoF table report, GRADE Evidence to Decision (EtD) frameworks report, use of resources assessment, and cost-effectiveness assessment. CPGs were classified according to the developing institution, rather than by broader health system sectors, to more accurately reflect the decentralized structure and variability of CPG development in Peru. Statistical analyses Statistical analyses were conducted using Stata v.17 software. Categorical variables were presented as both absolute and relative frequencies, and numerical variables were summarized using measures of central tendency and dispersion. Additionally, Fisher’s exact tests were performed to assess differences among the methodological characteristics of the CPGs across the developing organizations. A p-value < 0.05 was considered statistically significant. Results We assessed 312 records, from which 88 CPGs fulfilled the inclusion criteria (Fig 1 and S2 Table). The number of published CPGs has shown a decreasing trend over time: 39 in 2018–2019, 30 in 2020–2021, and 19 in 2022–2023 (Fig 2). Selection flowchart. CPG: clinical practice guideline. Trends in the publication of clinical practice guidelines (2018-2023), per local organizations. IETSI - EsSalud: Institute of Health Technology Assessment and Research of the Social Security Health Insurance; INS: National Institute of Health of the Ministry of Health; DGIESP: General Directorate of Strategic Health Interventions of the Ministry of Health. Most of the included CPGs were developed by the Institute of Health Technology Assessment and Research (IETSI, for its initials in Spanish) of the Peruvian Social Security Health Insurance (EsSalud) (60.2%), followed by hospitals of the Ministry of Health of Peru (17.1%), the AUNA Peru Network (a private healthcare network primarily focused on oncology) (9.1%), the National Institute of Health (INS, for its initials in Spanish) of the Ministry of Health (9.1%), the General Directorate of Strategic Health Interventions (DGIESP, for its initials in Spanish) of the Ministry of Health (2.3%), and the Peruvian Society of Neurology (a private professional organization dedicated to neurology) (2.3%). The most common covered area among the CPGs was oncology (20.5%), and most of the CPGs (96.6%) included disease management. Regarding authorship, the identification of authors and their respective roles were detailed in 97.7% and 92% of the CPGs, respectively. Among CPGs that detailed the author’s roles, 100% reported having at least one clinical expert, 97.5% included at least one CPG development methodologist, and 3.7% included a patient representative. The median total number of authors was 13.5 (interquartile range [IQR]: 11–18), while the median numbers of clinical experts and methodologists were 9 (IQR: 6–12) and 3 (IQR: 2–5), respectively (Table 1). 10.1371/journal.pone.0339861.t001Table 1General characteristics of Peruvian clinical practice guidelines (n = 88).Characteristics an (%)Local organization that developed the CPG IETSI – EsSalud53 (60.2) Hospitals of the Ministry of Health15 (17.1) AUNA Peru Network b8 (9.1) INS – Ministry of Health8 (9.1) DGIESP – Ministry of Health2 (2.3) Peruvian Society of Neurology b2 (2.3)Year of publication 2018–201939 (44.3) 2020–202130 (34.1) 2022–202319 (21.6)Type of CPG c De novo64 (72.7) Adapted from previous CPGs28 (31.8) Adopted from previous CPGs12 (13.6)Area addressed Oncology18 (20.5) Ophthalmology11 (12.5) Cardiology7 (8.0) Neurology7 (8.0) Others45 (51.1)Target population Adults61 (69.3) Children10 (11.4) Adults and children7 (8.0) Not specified10 (11.4)Scenario addressed c Prevention21 (23.9) Diagnosis52 (59.1) Management85 (96.6) Follow-up15 (17.1)Authorship c The identification of authors was detailed86 (97.7) The roles of the authors were detailed81 (92.0)Role of authors c At least one author was a clinical expert (n = 81)81 (100.0) At least one author was a methodologist (n = 81)79 (97.5) At least one author was a patient (n = 81)3 (3.7) At least one author had another role (n = 81)63 (77.8)Number of authors d Total authors (n = 86)13.5 (11 - 18) Clinical experts (n = 78)9 (6 - 12) Methodologists (n = 76)3 (2 - 5) Patients (n = 3)6 (2 - 7) Others (n = 59)1 (1 - 2)IETSI – EsSalud: Institute of Health Technology Assessment and Research of the Social Security Health Insurance; INS: National Institute of Health of the Ministry of Health; DGIESP: General Directorate of Strategic Health Interventions of the Ministry of Health.aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=).bPrivate organizations.cThe categories were not mutually exclusive.dMedian (Interquartile range). General characteristics of Peruvian clinical practice guidelines (n = 88). IETSI – EsSalud: Institute of Health Technology Assessment and Research of the Social Security Health Insurance; INS: National Institute of Health of the Ministry of Health; DGIESP: General Directorate of Strategic Health Interventions of the Ministry of Health. aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=). bPrivate organizations. cThe categories were not mutually exclusive. dMedian (Interquartile range). Clinical flowcharts were included in 87.5% of CPGs, and 85.2% clearly outlined the clinical questions addressed, with a median of seven (IQR: 6–9) questions per CPG. Additionally, 94.3% of the CPGs differentiated between strong recommendations (median: 4, IQR: 2–8), conditional recommendations (median: 4, IQR: 2–8), and good clinical practices (median: 14, IQR: 4–23). External reviewers assessed 89.8% of the CPGs. While no CPG reported receiving industry funding, 12.5% did not specify their funding sources. Furthermore, 9.1% did not disclose whether the authors had any conflicts of interest (Table 2). 10.1371/journal.pone.0339861.t002Table 2Specific characteristics of Peruvian clinical practice guidelines (n = 88).Characteristicsan (%)Included clinical flowchart77 (87.5)Clearly identifies the assessed clinical questions75 (85.2)Number of clinical questionsb Total clinical questions (n = 75)7 (6 - 9) Intervention questions (n = 75)5 (4 - 7) Diagnostic questions (n = 75)1 (0 - 3)Show a table with all the recommendations82 (93.2)Clear differentiation between strong recommendations, conditional recommendations, and good clinical practices83 (94.3)Number of recommendations based on the GRADE methodologyb Strong recommendations (n = 83)4 (2 - 8) Conditional recommendations (n = 83)4 (2 - 8) Good clinical practices (n = 83)14 (4 - 23)Funding Not specified11 (12.5) Declared funding but not from the industry77 (87.5) Declared industry funding0 (0.0)Declaration of author’s conflicts of interest Did not declare author’s conflicts of interest8 (9.1) Declared that no author had conflicts of interest70 (79.5) Declared that some authors had conflicts of interest10 (11.4)Identification of external reviewers79 (89.8)CPG: Clinical practice guideline: GRADE: Grading of Recommendations, Assessment, Development, and Evaluations.aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=).bMedian (Interquartilic range). Specific characteristics of Peruvian clinical practice guidelines (n = 88). CPG: Clinical practice guideline: GRADE: Grading of Recommendations, Assessment, Development, and Evaluations. aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=). bMedian (Interquartilic range). Regarding the methodological characteristics of the CPGs, 23.7% employed three or more search engines, with higher frequencies observed in CPGs from the INS-Ministry of Health and AUNA Peru Network. Additionally, 88.2% of the CPGs presented their search strategies, with IETSI-EsSalud and the INS-Ministry of Health achieving 100% adherence to this practice. The reporting of risk of bias assessments varied across organizations, ranging from 0% to 100% of the CPGs (Table 3). 10.1371/journal.pone.0339861.t003Table 3Methodological characteristics of Peruvian clinical practice guidelines (n = 88).CharacteristicsaTotalIETSI – EsSaludHospitals of the Ministry of HealthAUNA Peru NetworkINS – Ministry of HealthOthersbp-valuecn (%)n (%)n (%)n (%)n (%)n (%)Number of search engines used to answer each clinical question (n = 76)d <0.001 123 (30.3)22 (44.0)0 (0.0)1 (14.3)0 (0.0)0 (0.0) 229 (38.2)25 (50.0)3 (37.5)0 (0.0)1 (12.5)0 (0.0) ≥ 318 (23.7)3 (6.0)2 (25.0)4 (57.1)7 (87.5)2 (66.7) Not mentioned6 (7.9)0 (0.0)3 (37.5)2 (28.6)0 (0.0)1 (33.3)Identification of search strategies for clinical questions (n = 76)d67 (88.2)50 (100.0)5 (62.5)2 (28.6)8 (100.0)2 (66.7) <0.001 Identification of risk of bias assessment of the included studies (n = 76)d58 (76.3)50 (100.0)4 (50.0)0 (0.0)2 (25.0)2 (66.7) <0.001 Mentioned the use of GRADE methodology83 (94.3)52 (98.1)12 (80.0)8 (100.0)8 (100.0)3 (75.0)0.084Identification of SoF tables61 (69.3)47 (88.7)5 (33.3)0 (0.0)7 (87.5)2 (50.0) <0.001 The minimal important difference was established for at least one clinical question5 (5.7)5 (9.4)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0.888EtD and criteria for resource use and cost-effectiveness <0.001 Did not conduct EtD34 (38.6)12 (22.6)11 (73.3)7 (87.5)2 (25.0)2 (50.0) Conducted EtD but did not mention any local costs19 (21.6)12 (22.6)1 (6.7)0 (0.0)6 (75.0)0 (0.0) Conducted EtD and mentioned only direct costs31 (35.2)25 (47.2)3 (20.0)1 (12.5)0 (0.0)2 (50.0) Conducted EtD and specified the cost of avoiding or causing a particular outcome0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Conducted EtD and searched for economic studies3 (3.4)3 (5.7)0 (0.0)0 (0.0)0 (0.0)0 (0.0) Conducted EtD and performed economic analyses1 (1.1)1 (1.9)0 (0.0)0 (0.0)0 (0.0)0 (0.0)GRADE: Grading of Recommendations, Assessment, Development, and Evaluations; EtD: Evidence to Decision; IETSI – EsSalud: Institute of Health Technology Assessment and Research of the Social Security Health Insurance; INS: National Institute of Health of the Ministry of Health; SoF: Summary of Findings.aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=).bGeneral Directorate of Strategic Health Interventions of the Ministry of Health (DGIESP) and Peruvian Society of Neurology.cFisher’s exact test.dThirteen CPGs were excluded because they were adopted (did not conduct searches or analyses to address their clinical questions). Methodological characteristics of Peruvian clinical practice guidelines (n = 88). GRADE: Grading of Recommendations, Assessment, Development, and Evaluations; EtD: Evidence to Decision; IETSI – EsSalud: Institute of Health Technology Assessment and Research of the Social Security Health Insurance; INS: National Institute of Health of the Ministry of Health; SoF: Summary of Findings. aFor the variables where information could not be obtained from all the CPGs, the number of CPGs from which information was available is indicated in parentheses (n=). bGeneral Directorate of Strategic Health Interventions of the Ministry of Health (DGIESP) and Peruvian Society of Neurology. cFisher’s exact test. dThirteen CPGs were excluded because they were adopted (did not conduct searches or analyses to address their clinical questions). Of the included CPGs, 94.3% indicated using the GRADE methodology, but only 69.3% presented SoF tables, with variations ranging from 0% to 88.7% across organizations. Only 5.7% of the CPGs established minimally important differences for interpreting the evidence, and this practice was exclusively observed in IETSI-EsSalud. Regarding the EtD framework, 38.6% did not use this framework, with lower frequencies observed in IETSI-EsSalud (22.6%) and the INS-Ministry of Health (25.0%). IETSI-EsSalud was the only organization that sought economic evidence in three CPGs (3.4%) and conducted an economic evaluation in one CPG (1.1%) (Table 3). Discussion Our study aimed to describe the characteristics of CPGs developed in Peru and published from 2018 to December 2023. We included 88 CPGs, which exhibited a declining trend in their number over time. Of these CPGs, 60.2% were developed by IETSI-EsSalud. We observed inter-institutional variability in the use of search engines, transparency of search strategies, and risk assessment for bias. Furthermore, 94.3% of the CPGs reported using the GRADE methodology for formulating recommendations; however, only 69.3% included SoF tables, and 61.4% utilized the EtD framework. Additionally, there was a notable lack of economic studies or evaluations within the CPGs. We identified a downward trend in the number of published CPGs in Peru between 2018 and 2023. Part of this decline can be attributed to the COVID-19 pandemic, which could have hindered the development of meetings of CPG developer groups, previously conducted in person, and led to a redirection of health priorities (prompting decision-making organizations like IETSI-EsSalud or Ministry of Health) to produce quicker evidence synthesis documents [15,16]. Additionally, other factors could have influenced this trend, such as the instability of Peruvian public organizations [17]. Regarding methodological aspects, only 23.7% of the CPGs employed three or more search engines for evidence identification, and the same percentage did not include a bias risk assessment. These limitations are critical, as thorough search and bias assessment are essential components of SRs [18]. Their absence could potentially undermine the trustworthiness of the SRs conducted by CPGs, particularly when identifying primary studies [19]. The GRADE system provides a structured, explicit, and transparent method for evaluating evidence certainty and formulating recommendations [20]. Despite national regulations in Peru mandating that CPG development should be based on SRs and utilize the GRADE methodology for recommendations [9], significant variability exists in the CPG development process. This variability may reflect limited enforcement mechanisms and the decentralized nature of CPG development in Peru. Institutions such as EsSalud, which have internal mandates and established technical methodological teams [21], have shown greater adherence to GRADE components. In contrast, other institutions may lack technical capacity or internal regulations that reinforce adherence to these national standards. These regulatory and institutional differences likely contribute to the heterogeneity observed in the use of GRADE components across CPGs. We found that 94.3% of the CPGs reported using the GRADE methodology for their recommendations, following regulatory standards. However, only 69.3% included SoF tables, and 61.4% performed EtD frameworks. This indicates that many Peruvian CPGs were published without fulfilling the minimum requirements outlined by the GRADE guidance group for the use of the GRADE methodology, specifically the inclusion of SoF tables and EtD frameworks [22]. This shortfall may be attributed to limited methodological capacity, particularly a lack of trained methodologists in GRADE methodology, as reported in other countries in the region, such as Brazil, where despite centralized process for CPG development, there is a persistent shortage of qualified human resources and limited investment in capacity-building for CPG development [23]. Similar capacity constraints have also been observed across Latin America. For instance, a regional analysis of CPGs published between 2011 and 2017 found that many were developed with limited technical and institutional support, insufficient training in evidence-based methodologies, and minimal application of GRADE, compromising both methodological rigor and transparency [24]. In Mexico, however, the adherence to the GRADE methodology was even lower, with only 29.1% of CPGs claiming to use it, which highlights an even greater issue in guideline implementation [5]. This issue has been similarly identified in reviews of health technology assessments in Peru (4.6%) [25]. Similar findings have also been reported in other studies examining international CPGs, such as those developed in Australia [26], China [27], and in specific areas like trauma surgery [28] and pressure injury prevention [29] that claimed to use the GRADE methodology. However, the implementation of the GRADE methodology differed across these CPGs, with some incorrectly applying GRADE and modifying certain elements of the GRADE process. The absence of SoF tables and EtD frameworks in a substantial proportion of CPGs may reduce their practical utility for clinicians and policymakers [20]. SoF tables synthesize the key findings in an accessible format, facilitating transparent and rapid interpretation of the certainty of evidence and magnitude of effects [30]. Likewise, EtD frameworks support decision-makers in adapting recommendations to local contexts by explicitly considering factors such as resource availability, feasibility, equity, and patient preferences [31]. Without these tools, recommendations may lack clarity, contextual relevance, or perceived credibility, potentially limiting their implementation and impact in real-world settings [31]. In addition to assessing benefits and harms, economic analysis is crucial for decision-making, especially in resource-limited settings, where judicious resource management is essential to ensure equitable decisions. The GRADE guidelines include resource use and cost-benefit considerations among the EtD criteria [32,33]. In our study, only 39.7% of CPGs assessed resource use, with only three CPGs searching for economic studies, and one conducting a budget impact analysis. Similarly, a previous study found that none of the Peruvian health technology assessments sought or conducted economic studies, and 85.5% only presented the costs of health technologies [25]. This gap may reflect structural limitations, such as a shortage of trained personnel in health economics, the absence of clear institutional methodological CPGs for economic evidence, and the lack of structured economic data from Peruvian healthcare services. These challenges are not unique to Peru and have been reported in other countries, such as Brazil, where the need to invest in capacity-building and methods development for economic evaluation in CPGs has also been emphasized [23]. Furthermore, insufficient training and fragmented institutional processes have been identified as key obstacles to CPG development across Latin America [24]. Efforts to standardize CPG development in Latin America have employed various strategies, gradually shifting toward evidence-based practices since 2014 [34]. This shift, driven by academic institutions and research groups, has prioritized guideline adaptation, adoption, or de novo development, supported by the creation of methodological manuals [34]. This approach has gained traction across the region, with countries like Brazil [35], Colombia [36], Chile [13], Mexico [5], Argentina [12], and Peru [9] establishing standards for both CPG development and implementation of CPGs [34]. In Peru, the first technical document for CPGs development, issued in 2005 by the Ministry of Health, classified evidence using the U.S. Preventive Services Task Force model but lacked robust processes for clinical question formulation or guideline adaptation [37]. For example, this document described the methodology as a literature review on the pathology of interest, applying recommendation levels based on study design and findings, without a clear and systematic process for reaching conclusions. Moreover, the adaptation of CPGs lacked a systematic approach, as no explicit criteria were established for selecting international CPGs. Additionally, the methodological process was not required to be explicitly presented; instead, the CPG document was structured as a literature summary covering aspects such as the condition’s name, definition, associated risk factors, clinical presentation, diagnosis, auxiliary tests, management, complications, referral and counter-referral, flowchart or algorithm, and references [37]. The 2015 technical document marked progress by incorporating PICO (Population, Intervention, Comparator, Outcome) questions, systematic reviews, and the GRADE approach [9]. Despite improvements, challenges persist in ensuring the consistent production and implementation of evidence-based CPGs. Based on our findings, we propose a strategic roadmap to improve the development and implementation of CPGs in Peru. Improving CPG management in Peru requires strengthening the training of methodologists in evidence synthesis, integrating economic analyses into decision-making, and ensuring greater consistency in CPG development. Addressing these methodological gaps will require coordinated efforts from key institutions such as EsSalud and the Ministry of Health of Peru. EsSalud, as the largest social health insurance provider and the institution with the most evidence-based CPGs developed using the GRADE methodology, could establish specialized teams of trained methodologists to oversee the CPG development process and ensure adherence to evidence-based standards. Meanwhile, the Ministry of Health of Peru, could implement regulatory policies mandating the use of SRs and economic evaluations in all national CPGs. Furthermore, both institutions could collaborate with academic centers to develop standardized training programs for CPG developers, promoting the use of structured methodologies and transparent decision-making processes. Another key strategy would be the creation of a centralized repository for CPGs, ensuring accessibility, periodic updates, and methodological consistency across institutions. Our study contributes to ongoing discussions on improving CPG quality and implementation in Peru by providing a snapshot of current trends and identifying critical gaps that need to be addressed to enhance the evidence base for healthcare decision-making. Limitations and strengths This study has certain limitations that should be acknowledged. Firstly, we only included CPGs that explicitly stated they had conducted SRs to formulate recommendations, aligning with current international and national definitions. As a result, documents that did not meet these criteria or were not available in full-text online were excluded from our analysis. Second, we did not use quality assessment tools such as the Appraisal of Guidelines for Research and Evaluation II (AGREE II) because our focus was on specific methodological aspects, particularly those related to GRADE, in line with the Peruvian guideline development manual, rather than an assessment of overall quality. AGREE II provides a broad evaluation framework, but its combination of multiple domains and reported limitations, such as subjective scoring and lack of weighting [38], may reduce its utility for focused methodological analysis. Similarly, we did not evaluate the quality of recommendations, good clinical practices, conflict of interest management, adherence measurement efforts, or implementation strategies, leaving these areas for future research on Peruvian CPGs. Regarding the selection of 2018 as the starting year for assessing the CPGs, we chose this date because it is likely that the first national CPGs fully developed under the methodological standards established in 2015 [9] were published from 2018 onward. This is based on the understanding that national CPG developers began applying the GRADE methodology in 2016, allowing time for training and adaptation. However, we acknowledge that excluding older CPGs may have influenced the results of our analysis. Finally, our search strategy primarily relied on Google and publicly accessible local repositories, excluding PubMed, Scopus, and other search engines, as CPGs in Peru are not required to be published as journal articles. Consequently, some CPGs may have been omitted if they were not indexed by Google, if their identification as journal articles in the excluded search engines was faster, or if they were only accessible through institutional repositories or other less visible platforms. Additionally, while CPGs are often grouped by health system sector (e.g., Ministry of Health, Social Security, or private sector), in this study we classified them by institution to better reflect the decentralized nature of CPG development in Peru. This approach allowed for a more accurate characterization of methodological differences among the various entities responsible for their development. Despite these limitations, this study is the first to assess the methodological characteristics of Peruvian CPGs following the national norms published in 2015. We conducted data extraction and assessment in duplicate, ensuring reliability and standardization. Our findings shed light on methodological challenges in Peruvian CPGs, which may extend to other regions, emphasizing the need for improved oversight in CPG development and enhanced training for methodologists. Conclusions In conclusion, we found a decline in the publication of CPGs in Peru, likely impacted by the COVID-19 pandemic and challenges faced by the Peruvian health systems. Many CPGs lack clear search strategies and risk of bias assessments. While many CPGs claimed adherence to the GRADE methodology, a notable percentage failed to provide SoF tables, utilize the EtD framework, or use minimal important differences; and only a few CPGs searched or performed economic analyses. Addressing these shortcomings is crucial for advancing the development of rigorous CPGs that facilitate equitable healthcare delivery in Peru. Supporting information Search strategies. (DOCX) Table of excluded CPGs. (DOCX) Dataset of Peruvian Clinical Practice Guidelines (2018–2023). (XLSX) PRISMA for Scoping Reviews (PRISMA-ScR). (DOCX) 26 Nov 2024 Dear Dr. Taype-Rondan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please check the reviewers' comments and modify the manuscript accordingly. I particularly support suggestions regarding the contextualization of this issue. You should compile data about previous efforts to standardize Clinical Practice Guidelines (CPGs) in Peru and other South American countries. Regarding discussion and conclusions, what actions should be expected in the following years? How could this study contribute to improving CPG management in Peru? Please add these topics in the discussion. Please submit your revised manuscript by Jan 10 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alexis G. Murillo Carrasco Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Thank you for stating the following in the Competing Interests section: I have read the journal's policy and the authors of this manuscript have the following competing interests: ABC, JRM, LCR and ATR have participated in the development of clinical practice guidelines for the Institute of Health Technology Assessment and Research (IETSI) of EsSalud and have received compensation for their work. The authors declare no additional potential conflicts of interest related to this study. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** Reviewer #1: good work done by you and your team member and also congratulation to you. ............................................................................................................................. Reviewer #2: Overall this is a good one and address some of questions I interested in. The following is my opinion that I think can make it better: 1. Please onvert all dataset variable names from Spanish to English, as shown in the provided Excel file, to improve accessibility for international researchers. This translation will help external reviewers and collaborators better understand the variables and verify the data. 2. The introduction mentions deficiencies in methodology found in previous studies. To provide context, consider creating a table or a brief review summarizing these past methodological shortcomings. Then, compare these with the findings from your current study. This addition would be beneficial for future researchers by highlighting patterns and supporting efforts to standardize Clinical Practice Guidelines (CPGs) in South America. 3. What are the standards for CPGs in Peru versus other countries? Provide an overview of international standards for CPGs, if available, and discuss the differences with Peruvian standards. Consider sharing your perspective on what constitutes an ideal standard for CPGs, with a critical analysis. For instance, how might the CPGs from countries like Japan or the U.S. be considered superior, and what aspects could be improved? 4. Expand on the data collection process, specifically the consensus method. Include details on how consensus was reached, the criteria used, and the process undertaken to ensure quality in data collection. This additional information would help demonstrate the rigor applied to maintain data reliability. 5. In Table 3, in addition to the p-values and percentages, please include the standard deviation and 95% confidence intervals for each result. This added statistical detail will provide a clearer picture of the variability and confidence in the results. Reviewer #3: This is an interesting scoping review that describes the methodological characteristics of Peruvian clinical practice guidelines. To further strengthen the manuscript, please see the comments and suggestions below. Introduction • The Introduction lacks literature on previous studies. • Additional background and explanation on what is considered as an ideal/standard CPG and what is the standard content of CPGs would be helpful to provide additional context. Also, it would be helpful if the authors specify what methodological deficiencies are usually observed in local CPGs. Methods • Page 6, Line 80: Any rationale for considering 2018 as the start year for assessing the CPGs when the standardized methodology document from Ministry of Health was established in 2015? • Was the literature search not conducted in other search engines including PubMed, SCOPUS etc.? • Why were CPGs with partial updates not included? Wouldn’t the partial updates also indicate changes based on the 2015 standardized methodology from Ministry of Health? Results • Any reason the sample size (n) was equal to 85 and not 88 for Tables 2 and 3? Discussion • The Discussion should highlight the implications of this study and how the results would help in bringing positive changes related to CPGs. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: No Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. 10 Jan 2025 Editor’s comments: 1. You should compile data about previous efforts to standardize Clinical Practice Guidelines (CPGs) in Peru and other South American countries. Regarding discussion and conclusions, what actions should be expected in the following years? How could this study contribute to improving CPG management in Peru? Please add these topics in the discussion. Answer: Thanks for your comment. We have added the following information: “Efforts to standardize CPG development in Latin America have employed various strategies, gradually shifting toward evidence-based practices since 2014 [30]. This shift, driven by academic institutions and research groups, has prioritized guideline adaptation, adoption, or de novo development, supported by the creation of methodological manuals [30]. This approach has gained traction across the region, with countries like Brazil [31], Colombia [32], Chile [13], Mexico [5], Argentina [12], and Peru [9] establishing standards for both CPG development and implementation of CPGs [30]. In Peru, the first technical document, issued in 2005, classified evidence using the U.S. Preventive Services Task Force model but lacked robust processes for clinical question formulation or guideline adaptation [33]. The 2015 technical document marked progress by incorporating PICO (Population, Intervention, Comparator, Outcome) questions, systematic reviews, and the GRADE approach [9]. Despite improvements, challenges persist in ensuring the consistent production and implementation of evidence-based CPGs. Improving CPG management in Peru should focus on enhancing the training of methodologists in evidence synthesis, increasing the integration of economic analysis in decision-making, and ensuring greater consistency in guideline development processes. In the coming years, expected actions include greater collaboration between institutions, strengthening oversight mechanisms, and the continued development of robust training programs for CPG developers. Our study contributes to ongoing discussions on improving CPG quality and implementation in Peru by providing a snapshot of current trends and identifying critical gaps that need to be addressed to enhance the evidence base for healthcare decision-making.” Journal Requirements: 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf Answer: We verified that our manuscript follows PLOS ONE’s style requirements. 2. Thank you for stating the following in the Competing Interests section: I have read the journal's policy and the authors of this manuscript have the following competing interests: ABC, JRM, LCR and ATR have participated in the development of clinical practice guidelines for the Institute of Health Technology Assessment and Research (IETSI) of EsSalud and have received compensation for their work. The authors declare no additional potential conflicts of interest related to this study. Please confirm that this does not alter your adherence to all PLOS ONE policies on sharing data and materials, by including the following statement: ""This does not alter our adherence to PLOS ONE policies on sharing data and materials.” (as detailed online in our guide for authors http://journals.plos.org/plosone/s/competing-interests). If there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared. Please include your updated Competing Interests statement in your cover letter; we will change the online submission form on your behalf. Answer: We have updated the competing interests section and included it in the cover letter: “ABC, JRM, LCR and ATR have participated in the development of clinical practice guidelines for the Institute of Health Technology Assessment and Research (IETSI) of EsSalud and have received compensation for their work. The authors declare no additional potential conflicts of interest related to this study. This does not alter our adherence to PLOS ONE policies on sharing data and materials”. Reviewers’ comments: R2.1: Please convert all dataset variable names from Spanish to English, as shown in the provided Excel file, to improve accessibility for international researchers. This translation will help external reviewers and collaborators better understand the variables and verify the data. Answer: We changed all dataset variable names to English. R2.2: The introduction mentions deficiencies in methodology found in previous studies. To provide context, consider creating a table or a brief review summarizing these past methodological shortcomings. Then, compare these with the findings from your current study. This addition would be beneficial for future researchers by highlighting patterns and supporting efforts to standardize Clinical Practice Guidelines (CPGs) in South America. Answer: Thanks for your comment. We have added the following information to the Introduction section: “Common shortcomings include unclear processes for formulating recommendations [4-6], inadequate systematic searches and selection criteria [4,5], limited consideration of evidence strengths and limitations [4-6], and failure to incorporate patients' preferences [4,6]. In Peru, an evaluation of 17 CPGs published by the Ministry of Health between 2009 and 2014 revealed similar deficiencies [7], including a lack of information about the guideline development team, minimal use of evidence, and unclear recommendation processes [7]. A further study of 31 CPGs developed by the Peruvian Social Health Insurance System (EsSalud) up to December 2015 reported gaps in evidence-based frameworks and inconsistent reporting of recommendations [8].” Also, we have added the following information to the Discussion section: “This shortfall may be attributed to a lack of trained methodologists in GRADE methodology, as reported in other countries in the region, such as Brazil [22], In Mexico, however, the adherence to the GRADE methodology was even lower, with only 29.1% of CPGs claiming to use it, which highlights an even greater issue in guideline implementation [5]. This issue has been similarly identified in reviews of health technology assessments in Peru (4.6%) [23].” R2.3: What are the standards for CPGs in Peru versus other countries? Provide an overview of international standards for CPGs, if available, and discuss the differences with Peruvian standards. Consider sharing your perspective on what constitutes an ideal standard for CPGs, with a critical analysis. For instance, how might the CPGs from countries like Japan or the U.S. be considered superior, and what aspects could be improved? Answer: Thanks for your comment. We have added the following information in the Introduction section: “Internationally, institutions such as the World Health Organization (WHO) [10], National Institute for Health and Care Excellence (NICE) in the UK [11], and regional organizations such as the Ministry of Health of Argentina [12] and Chile [13] follow rigorous methodologies emphasizing transparency, evidence quality assessment, and regular updates. While Peru's standards have advanced, they could benefit from greater alignment with these international practices, ensuring guidelines remain evidence-based and relevant.” We also have added information in the Discussion section: “Efforts to standardize CPG development in Latin America have employed various strategies, gradually shifting toward evidence-based practices since 2014 [30]. This shift, driven by academic institutions and research groups, has prioritized guideline adaptation, adoption, or de novo development, supported by the creation of methodological manuals [30]. This approach has gained traction across the region, with countries like Brazil [31], Colombia [32], Chile [13], Mexico [5], Argentina [12], and Peru [9] establishing standards for both CPG development and implementation of CPGs [30]. In Peru, the first technical document, issued in 2005, classified evidence using the U.S. Preventive Services Task Force model but lacked robust processes for clinical question formulation or guideline adaptation [33]. The 2015 technical document marked progress by incorporating PICO (Population, Intervention, Comparator, Outcome) questions, systematic reviews, and the GRADE approach [9]. Despite improvements, challenges persist in ensuring the consistent production and implementation of evidence-based CPGs. Improving CPG management in Peru requires a multi-faceted approach, including increased investment in training programs for methodologists, the creation of a central oversight body for quality assurance, and collaboration with international partners to adopt best practices. Future efforts should also focus on expanding access to data for economic evaluations and developing tailored tools to facilitate systematic resource use assessments.” R2.4: Expand on the data collection process, specifically the consensus method. Include details on how consensus was reached, the criteria used, and the process undertaken to ensure quality in data collection. This additional information would help demonstrate the rigor applied to maintain data reliability. Answer: Thanks for your comment. We added the following information: “In case of disagreements, consensus was reached through discussion among the investigators, followed by a second review of the data from the included CPGs to identify the precise information. To ensure the quality of the data collection process, a predefined set of criteria was applied to each variable. This included cross-checking the extracted information with the original documents, verifying consistency across multiple versions and journal articles of the CPGs, and ensuring the accuracy of all recorded data. If consensus could not be reached, another researcher (ATR) was consulted to resolve any uncertainties or clarify discrepancies in the data.” R2.5: In Table 3, in addition to the p-values and percentages, please include the standard deviation and 95% confidence intervals for each result. This added statistical detail will provide a clearer picture of the variability and confidence in the results. Answer: Thank you for your suggestion. However, the variables presented in Table 3 are categorical and expressed as percentages. Therefore, it is not possible to calculate standard deviations or 95% confidence intervals for these results. R3.1: Introduction • The Introduction lacks literature on previous studies. Answer: We detailed the information of previous studies: “]. In Peru, an evaluation of 17 CPGs published by the Ministry of Health between 2009 and 2014 revealed similar deficiencies [7], including a lack of information about the guideline development team, minimal use of evidence, and unclear recommendation processes [7]. A further study of 31 CPGs developed by the Peruvian Social Health Insurance System (EsSalud) up to December 2015 reported gaps in evidence-based frameworks and inconsistent reporting of recommendations [8].” R3.2: Introduction • Additional background and explanation on what is considered as an ideal/standard CPG and what is the standard content of CPGs would be helpful to provide additional context. Also, it would be helpful if the authors specify what methodological deficiencies are usually observed in local CPGs. Answer: Thanks for your comment. We added the following information: “A trustworthy CPG adheres to these standards that emphasize key components including clearly defined clinical questions, systematic literature searches, the use of a grading system for evidence, explicit criteria for formulating recommendations, external review, and a structured process for updates [1,2].” R3.3: Methods • Page 6, Line 80: Any rationale for considering 2018 as the start year for assessing the CPGs when the standardized methodology document from Ministry of Health was established in 2015? Answer: Thanks for your comment. We considered it reasonable that, although the new standards were established in 2015, they would begin to be applied starting in 2016, allowing time for training and adaptation. Therefore, the first guidelines fully developed under these standards would likely be published from 2018 onward, making this a more appropriate starting point for our analysis. R3.4: Methods • Was the literature search not conducted in other search engines including PubMed, SCOPUS etc.? Answer: Thanks for your comment. In Peru, clinical practice guidelines are not required to be published as journal articles. When they are published in this format, they often present only a summary (a brief justification for each recommendation) of the guideline content rather that the complete document. Therefore, we prioritized searches on local websites, Google, and Google Scholar, where full versions of the guidelines are more likely to be available. This approach allowed us to access the comprehensive documents necessary for our analysis. R3.5: Methods • Why were CPGs with partial updates not included? Wouldn’t the partial updates also indicate changes based on the 2015 standardized methodology from Ministry of Health? Answer: Thanks for your comment. Since the standardized methodology was predominantly implemented from 2018 onward, there have not been frequent updates to previous guidelines published under this framework. We identified only two partially updated guidelines developed by the Social Health Insurance of Peru (IETSI-EsSalud). which are listed in the “S2 Table: Table of excluded CPGs”. The first versions of these guidelines, published in 2018, already followed the GRADE methodology, aligning with the standardized approach. The partial updates focused primarily on updating evidence supporting specific recommendations that could influence their direction (e.g., recommend/suggest or not recommend/suggest), rather than revising the overall methodology. Therefore, we deemed it unnecessary to include these partial updates, as they did not represent comprehensive methodological changes. R3.6: Results • Any reason the sample size (n) was equal to 85 and not 88 for Tables 2 and 3? Answer: Thank you for your comment. The sample size (n) in Table 2 and Table 3 is 88, not 85. We have made the necessary corrections. Additionally, we re-verified all the information in the Tables regarding percentage calculations (%), and only two corrections were made in Table 1 and Table 2. R3.7: Discussion • The Discussion should highlight the implications of this study and how the results would help in bringing positive changes related to CPGs. Answer: We have added the following information: “Efforts to standardize CPG development in Latin America have employed various strategies, gradually shifting toward evidence-based practices since 2014 [30]. This shift, driven by academic institutions and research groups, has prioritized guideline adaptation, adoption, or de novo development, supported by the creation of methodological manuals [30]. This approach has gained traction across the region, with countries like Brazil [31], Colombia [32], Chile [13], Mexico [5], Argentina [12], and Peru [9] establishing standards for both CPG development and implementation of CPGs [30]. In Peru, the first technical document, issued in 2005, classified evidence using the U.S. Preventive Services Task Force model but lacked robust processes for clinical question formulation or guideline adaptation [33]. The 2015 technical document marked progress by incorporating PICO (Population, Intervention, Comparator, Outcome) questions, systematic reviews, and the GRADE approach [9]. Despite improvements, challenges persist in ensuring the consistent production and implementation of evidence-based CPGs. Improving CPG management in Peru should focus on enhancing the training of methodologists in evidence synthesis, increasing the integration of economic analysis in decision-making, and ensuring greater consistency in guideline development processes Submitted filename: Response to reviewers.docx 27 Jan 2025 Dear Dr. Taype-Rondan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. In addition to the reviewer response already provided, please state in the limitations of this study your rationale for considering 2018 as the start year for assessing the CPGs and for not including Pubmed, Scopus, or other search engines. Please discuss more on suggestions to adress methodological issues in Peru, especially on how ESSALUD or Peruvian Health Minister could contribute to improve the elaboration of CPGs. Provide examples illustrating how the Peruvian first technical document lacked robust processes for formulating clinical questions or adapting guidelines. Please review the entire document ensuring all authors' comments are objective and highlight the methods used to identify shortcomings, specifying particular flaws where applicable. Please submit your revised manuscript by Mar 13 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org . When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols . We look forward to receiving your revised manuscript. Kind regards, Alexis G. Murillo Carrasco Academic Editor PLOS ONE Journal Requirements: Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes ********** Reviewer #2: This resubmission effectively addresses all of my and the other reviewers' previous concerns. The authors have demonstrated a thorough and systematic effort to resolve the issues raised, and the revised manuscript now provides a comprehensive overview of Peruvian CPG development and related methodological characteristics. I appreciate the detailed responses and thoughtful additions to the manuscript. However, upon further review, I believe the manuscript could be strengthened by explicitly acknowledging a potential bias in the search strategy. Specifically, as stated in the response: "In Peru, clinical practice guidelines are not required to be published as journal articles. When they are published in this format, they often present only a summary (a brief justification for each recommendation) of the guideline content rather than the complete document." This raises the concern that some relevant documents may not have been retrieved using Google as the primary search platform. There is a risk of missing guidelines that are either not indexed by Google or require access through less visible platforms or institutional repositories. I recommend adding a discussion point in the limitations section to explicitly address this potential bias and the limitations of the current search methodology. Furthermore, considering more comprehensive and systematic search techniques—such as web scraping or leveraging specialized databases—could be a valuable direction for future research. This approach would enhance the robustness of guideline retrieval and ensure better coverage. Overall, the authors have done an excellent job with this scoping review, and the manuscript offers valuable insights into Peruvian CPG development. I am confident in recommending it for acceptance with the above minor addition. Reviewer #3: (No Response) ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org 10 Feb 2025 Editor’s comments: 1. In addition to the reviewer response already provided, please state in the limitations of this study your rationale for considering 2018 as the start year for assessing the CPGs and for not including Pubmed, Scopus, or other search engines. Answer: Thanks for your comment. We added the following information in the Discussion section: “Regarding the selection of 2018 as the starting year for assessing the CPGs, we chose this date because it is likely that the first national CPGs fully developed under the methodological standards established in 2015 (9) were published from 2018 onward. This is based on the understanding that national CPG developers began applying the GRADE methodology in 2016, allowing time for training and adaptation. However, we acknowledge that excluding older CPGs may have influenced the results of our analysis. Finally, our search strategy primarily relied on Google and publicly accessible local repositories, excluding PubMed, Scopus, and other search engines, as CPGs in Peru are not required to be published as journal articles. Consequently, some CPGs may have been omitted if they were not indexed by Google, if their identification as journal articles in the excluded search engines was faster, or if they were only accessible through institutional repositories or other less visible platforms.” 2. Please discuss more on suggestions to adress methodological issues in Peru, especially on how ESSALUD or Peruvian Health Minister could contribute to improve the elaboration of CPGs. Answer: Thanks for your comment. We added the following information: “Improving CPG management in Peru requires strengthening the training of methodologists in evidence synthesis, integrating economic analyses into decision-making, and ensuring greater consistency in CPG development. Addressing these methodological gaps will require coordinated efforts from key institutions such as EsSalud and the Ministry of Health of Peru. EsSalud, as the largest social health insurance provider and the institution with the most evidence-based CPGs developed using the GRADE methodology, could establish specialized teams of trained methodologists to oversee the CPG development process and ensure adherence to evidence-based standards. Meanwhile, the Ministry of Health of Peru, could implement regulatory policies mandating the use of SRs and economic evaluations in all national CPGs. Furthermore, both institutions could collaborate with academic centers to develop standardized training programs for CPG developers, promoting the use of structured methodologies and transparent decision-making processes. Another key strategy would be the creation of a centralized repository for CPGs, ensuring accessibility, periodic updates, and methodological consistency across institutions.” 3. Provide examples illustrating how the Peruvian first technical document lacked robust processes for formulating clinical questions or adapting guidelines. Please review the entire document ensuring all authors' comments are objective and highlight the methods used to identify shortcomings, specifying particular flaws where applicable. Answer: Thanks for your comment. We added the following information: “For example, this document described the methodology as a literature review on the pathology of interest, applying recommendation levels based on study design and findings, without a clear and systematic process for reaching conclusions. Moreover, the adaptation of CPGs lacked a systematic approach, as no explicit criteria were established for selecting international CPGs. Additionally, the methodological process was not required to be explicitly presented; instead, the CPG document was structured as a literature summary covering aspects such as the condition's name, definition, associated risk factors, clinical presentation, diagnosis, auxiliary tests, management, complications, referral and counter-referral, flowchart or algorithm, and references [33].” Journal Requirements: 1. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Answer: We have verified all citations and found no references to retracted papers. Reviewers’ comments: R2.1: However, upon further review, I believe the manuscript could be strengthened by explicitly acknowledging a potential bias in the search strategy. Specifically, as stated in the response: "In Peru, clinical practice guidelines are not required to be published as journal articles. When they are published in this format, they often present only a summary (a brief justification for each recommendation) of the guideline content rather than the complete document." This raises the concern that some relevant documents may not have been retrieved using Google as the primary search platform. There is a risk of missing guidelines that are either not indexed by Google or require access through less visible platforms or institutional repositories. I recommend adding a discussion point in the limitations section to explicitly address this potential bias and the limitations of the current search methodology. Furthermore, considering more comprehensive and systematic search techniques—such as web scraping or leveraging specialized databases—could be a valuable direction for future research. This approach would enhance the robustness of guideline retrieval and ensure better coverage. Answer: Thanks for your comment. We added the following information in Discussion section: “Finally, our search strategy primarily relied on Google and publicly accessible local repositories, excluding PubMed, Scopus, and other search engines, as CPGs in Peru are not required to be published as journal articles. Consequently, some CPGs may have been omitted if they were not indexed by Google, if their identification as journal articles in the excluded search engines was faster, or if they were only accessible through institutional repositories or other less visible platforms.” Submitted filename: Response_to_reviewers_auresp_2.docx 30 Apr 2025 Dear Dr. Taype-Rondan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Kind regards, César Félix Cayo-Rojas, Ph.D. Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: All comments have been addressed Reviewer #4: (No Response) Reviewer #5: (No Response) ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #4: Partly Reviewer #5: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #4: No Reviewer #5: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #4: Yes Reviewer #5: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #4: Yes Reviewer #5: Yes ********** Reviewer #2: The manuscript is solid and good. I recommend this to the journal. I believed this topic will give some new perspective to the field. Reviewer #4: 1. Potential selection bias toward tertiary-level guidelines The study appears to be skewed toward clinical practice guidelines (CPGs) developed for tertiary-level care. It is unclear whether this is a reflection of availability or if there was an intentional search strategy targeting this level. The authors should clarify whether their inclusion criteria or sources were likely to miss guidelines developed for primary or secondary care. 2. Institution-based classification vs. Health sector grouping The decision to classify guidelines by specific institutions (e.g., IETSI, AUNA) may fragment the analysis and limit broader policy implications. Grouping by major health system sectors—such as social security, Ministry of Health, or private sector—could provide a more comprehensive and policy-relevant perspective. 3. Absence of a critical appraisal of methodological quality beyond grade While the focus is on GRADE components, the lack of a broader critical appraisal (e.g., AGREE II domains) limits the understanding of the overall methodological rigor of the guidelines. Including or at least discussing this could offer a more balanced assessment. 4. Lack of contextual data on developers' capacities The authors attribute deficiencies to limited methodological capacity but do not provide data to support this claim. Information on the availability of trained personnel, institutional mandates, or access to GRADE training would strengthen the interpretation. 5. Need for exploration of policy or regulatory drivers The manuscript could benefit from examining whether national regulations or incentive structures influence the adoption of GRADE components. This might help explain heterogeneity between institutions or sectors. 6. Unclear justification for excluding non-grade guidelines Excluding guidelines that did not claim to use GRADE may overlook potentially methodologically sound documents. The authors should clarify the rationale and implications of this exclusion on the comprehensiveness of the review. 7. Limited Exploration of Guideline Topics and Their Alignment with National burden of disease The paper does not analyze whether the guidelines reviewed align with national health priorities or the burden of disease in Peru. This would help assess their relevance and strategic focus. 8. Narrative synthesis could be strengthened with quantitative visualization A table or heatmap comparing GRADE components across institutions would enhance the clarity and accessibility of the findings, particularly for policymakers and non-specialist readers. 9. Insufficient discussion of implications for end-user utility While the absence of Summary of Findings (SoF) tables and EtD frameworks is highlighted, the practical implications for clinicians or decision-makers are not fully elaborated. This connection should be strengthened. 10. Need for a forward-looking roadmap or recommendations The discussion section would benefit from a more detailed set of recommendations or a roadmap for improving CPG development capacity in Peru, including possible institutional partnerships, technical training, or policy reforms. Reviewer #5: Results The table format should follow the journal's guidelines. It is recommended to adhere to the journal’s specific instructions or protocols for creating descriptive tables. In row 142, it is not necessary to explain what CPG stands for, as it has already been defined in the introduction and abstract. Please verify that all percentages add up to 100%. For example, in Table 1 (“Local organizations…”, “Area addressed”), the total is 100.1%. In Table 3, for the first variable (“Search engines used”), data from 76 CPGs is used, and 13 are marked as excluded. This presents an inconsistency with the stated total number of included CPGs (n = 88). Discussion Why are the results related to methodological differences in the “Identification of SoF tables” and “EtD and criteria for resource use and cost-effectiveness” not presented or discussed? (This also applies to the results section.) Although the focus is on CPGs from Peru, it is recommended to broaden the scope or highlight the relevance of the findings so that they may serve as a reference for other countries. Additionally, consider including as a limitation the fact that only CPGs with publicly available full-text versions were included. In Figure 1, please indicate the main reasons why the 206 documents were excluded. In Figure 2, include the percentage values for each color segment of the columns. This will make the figure easier to interpret. It is also important to show the sample size (“n”) for each year, as the results are currently presented in grouped form. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #4: No Reviewer #5: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/ . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org . Please note that Supporting Information files do not need this step. 9 Jul 2025 Response letter Dear Editor and reviewers, Thank you for your kind consideration. In this letter, we proceed to respond to the reviewers’ comments. Sincerely, Alvaro Taype-Rondan, corresponding author Reviewers’ comments: R4.1: Potential selection bias toward tertiary-level guidelines The study appears to be skewed toward clinical practice guidelines (CPGs) developed for tertiary-level care. It is unclear whether this is a reflection of availability or if there was an intentional search strategy targeting this level. The authors should clarify whether their inclusion criteria or sources were likely to miss guidelines developed for primary or secondary care. Answer: We added the following clarification in the Eligibility criteria section: “No restriction was applied regarding the level of healthcare (primary, secondary, or tertiary) for which the CPGs were intended.” This addition clarifies that our inclusion criteria and search strategy were not designed to target or exclude guidelines based on the level of care. R4.2: Institution-based classification vs. Health sector grouping The decision to classify guidelines by specific institutions (e.g., IETSI, AUNA) may fragment the analysis and limit broader policy implications. Grouping by major health system sectors—such as social security, Ministry of Health, or private sector—could provide a more comprehensive and policy-relevant perspective. Answer: Thank you for your observation. We agree that grouping by major health system sectors can be useful for policy analysis. However, in Peru, the development of clinical practice guidelines is highly decentralized. Each institution, whether public or private, operates independently and follows its own processes for guideline development. For example, IETSI is solely responsible for CPG development within EsSalud (the national social security system). In contrast, the Ministry of Health has at least three separate entities involved: DGIESP (part of the Ministry’s central office), INS (its research branch), and individual hospitals, which vary in methodological capacity. Similarly, private organizations such as AUNA and the Peruvian Society of Neurology develop CPGs through their own independent teams. Given this institutional heterogeneity, we chose to classify CPGs by developing institutions rather than by sector. This approach more accurately reflects current practices and allows identification of methodological strengths and gaps at the institutional level, differences that might be masked by broader sector-level groupings. We added the following clarifications to the manuscript: • At the Introduction section: “Despite the existence of this standard, CPG development in Peru remains decentralized. Different institutions, even within the same sector, develop CPGs independently, with distinct methodological teams and varying capacities. This institutional heterogeneity can influence the methodological quality and consistency of CPGs across the country”. • At the Data extraction section: “Variables of interest included the year of publication, covered area, developing organization (given that Peruvian health institutions operate with distinct processes and capacities)...” and “CPGs were classified according to the developing institution, rather than by broader health system sectors, to more accurately reflect the decentralized structure and variability of CPG development in Peru.” • At the Limitations section: “Additionally, while CPGs are often grouped by health system sector (e.g., Ministry of Health, Social Security, or private sector), in this study we classified them by institution to better reflect the decentralized nature of CPG development in Peru. This approach allowed for a more accurate characterization of methodological differences among the various entities responsible for their development.” R4.3: Absence of a critical appraisal of methodological quality beyond grade While the focus is on GRADE components, the lack of a broader critical appraisal (e.g., AGREE II domains) limits the understanding of the overall methodological rigor of the guidelines. Including or at least discussing this could offer a more balanced assessment. Answer: Thank you for your suggestion. While we acknowledge the value of AGREE II as a comprehensive tool for appraising guideline quality, our study focused on specific methodological characteristics, particularly those related to the use of GRADE. This focus aligns with the Peruvian guideline development manual, which explicitly recommends using GRADE to assess the certainty of evidence and formulate recommendations. We believe that AGREE II, by combining multiple domains, including reporting quality and editorial Independence, may dilute the focus on core methodological aspects. Our intention was not to provide a broad appraisal, but rather to identify and describe concrete methodological shortcomings that may compromise the reliability of the recommendations. In addition, as highlighted in a recent systematic review [38], AGREE II presents several limitations, such as the lack of guidance for the two overall assessments, the subjectivity in scoring, and the equal weighting of all items regardless of their relevance. These issues reduce its precision for detailed methodological evaluations. We have clarified this rationale in the limitations section of the manuscript: “Second, we did not use quality assessment tools such as AGREE II because our focus was on specific methodological aspects, particularly those related to GRADE, in line with the Peruvian guideline development manual, rather than an assessment of overall quality. AGREE II provides a broad evaluation framework, but its combination of multiple domains and reported limitations, such as subjective scoring and lack of weighting [38], may reduce its utility for focused methodological analysis.” 38. Hoffmann-Eßer W, Siering U, Neugebauer EA, Brockhaus AC, Lampert U, Eikermann M. Guideline appraisal with AGREE II: Systematic review of the current evidence on how users handle the 2 overall assessments. PLoS One. 2017;12(3):e0174831. doi: 10.1371/journal.pone.0174831. R4.4: Lack of contextual data on developers' capacities The authors attribute deficiencies to limited methodological capacity but do not provide data to support this claim. Information on the availability of trained personnel, institutional mandates, or access to GRADE training would strengthen the interpretation. Answer: In the manuscript, we now discuss how limited methodological capacity, including insufficient training in GRADE, has been identified as a major challenge in guideline development in other countries. We have clarified this in the discussion section: “This shortfall may be attributed to limited methodological capacity, particularly a lack of trained methodologists in GRADE methodology, as reported in other countries in the region, such as Brazil, where despite centralized process for CPG development, there is a persistent shortage of qualified human resources and limited investment in capacity-building for CPG development [23]. Similar capacity constraints have also been observed across Latin America. For instance, a regional analysis of CPGs published between 2011 and 2017 found that many were developed with limited technical and institutional support, insufficient training in evidence-based methodologies, and minimal application of GRADE, compromising both methodological rigor and transparency [24].” Also, we added the following information: “This gap may reflect structural limitations, such as a shortage of trained personnel in health economics, the absence of clear institutional methodological CPGs for economic evidence, and the lack of structured economic data from Peruvian healthcare services. These challenges are not unique to Peru and have been reported in other countries, such as Brazil, where the need to invest in capacity-building and methods development for economic evaluation in CPGs has also been emphasized [22] Furthermore, insufficient training and fragmented institutional processes have been identified as key obstacles to CPG development across Latin America [24].” 23. Colpani V, Kowalski SC, Stein AT, Buehler AM, Zanetti D, Côrtes G, et al. Clinical practice guidelines in Brazil – developing a national programme. Health Res Policy Sys. 2020;18(1):69. https://doi.org/10.1186/s12961-020-00582-0 24. Cabrera PA, Pardo R. Review of evidence based clinical practice guidelines developed in Latin America and Caribbean during the last decade: an analysis of the methods for grading quality of evidence and topic prioritization. Global Health. 2019;15(1):14. doi: 10.1186/s12992-019-0455-0. R4.5: Need for exploration of policy or regulatory drivers The manuscript could benefit from examining whether national regulations or incentive structures influence the adoption of GRADE components. This might help explain heterogeneity between institutions or sectors. Answer: We have now added a paragraph in the Discussion section: “The GRADE system provides a structured, explicit, and transparent method for evaluating evidence certainty and formulating recommendations [20]. Despite national regulations in Peru mandating that CPG development should be based on SRs and utilize the GRADE methodology for recommendations [9], significant variability exists in the CPG development process. This variability may reflect limited enforcement mechanisms and the decentralized nature of CPG development in Peru. Institutions such as EsSalud, which have internal mandates and established technical methodological teams [21], have shown greater adherence to GRADE components. In contrast, other institutions may lack technical capacity or internal regulations that reinforce adherence to these national standards. These regulatory and institutional differences likely contribute to the heterogeneity observed in the use of GRADE components across CPGs.” 9. Ministerio de Salud de Perú. Documento técnico: Metodología para la elaboración de guías de práctica clínica. Lima: Ministerio de Salud de Perú; 2015 [cited 2025 Jan 10]. Available from: https://www.gob.pe/institucion/minsa/informes-publicaciones/314118-documento-tecnico-metodologia-para-la-elaboracion-de-guias-de-practica-clinica 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026 21. Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI). Resolution No. 063-IETSI-ESSALUD-2021: Instruction No. 001-IETSI-ESSALUD-2021 for the development of clinical practice guidelines in EsSalud [Internet]. Lima: EsSalud; 2021 [cited 2025 Jul 5]. Available from: https://www.essalud.gob.pe/ietsi/pdfs/tecnologias_sanitarias/RS_063_IETSI_2021.pdf R4.6: Unclear justification for excluding non-grade guidelines Excluding guidelines that did not claim to use GRADE may overlook potentially methodologically sound documents. The authors should clarify the rationale and implications of this exclusion on the comprehensiveness of the review. Answer: We would like to clarify that our inclusion criteria did not require CPGs to explicitly state that they used GRADE. Instead, we included CPGs that reported basing their recommendations on systematic reviews (SRs), as required by Peruvian regulations since 2015 [9]. Our objective was to assess whether CPGs that claimed to use evidence-based methods (i.e., based their recommendations on SRs) incorporated core methodological components aligned with GRADE standards. This approach allowed us to evaluate the rigor and transparency of methodological implementation among CPGs that expressed an evidence-based intent. We have clarified this rationale in the Eligibility criteria section: “We included Peruvian CPGs that reported basing their recommendations on SRs, an essential component of evidence-based CPG development. This approach allowed us to focus on CPGs with an evidence-based intent and assess whether they incorporated key methodological components aligned with international standards [10-13] and the national regulations for CPG development in Peru [9].” In addition, we evaluated whether each CPG explicitly mentioned the use of the GRADE methodology (Table 3, 4th variable). Although most CPGs did so (94.3%), a small number of included CPGs based their recommendations on SRs without referring to GRADE. Therefore, our inclusion criterion was not restricted to the use of GRADE, but rather to the presence of SR-based recommendations, which allowed us to explore both the adoption and the use of GRADE components in eligible CPGs. R4.7: Limited Exploration of Guideline Topics and Their Alignment with National burden of disease The paper does not analyze whether the guidelines reviewed align with national health priorities or the burden of disease in Peru. This would help assess their relevance and strategic focus. Answer: Thanks for your comment. We agree that analyzing the alignment of CPG topics with national health priorities and disease burden is an important area of exploration. However, this was beyond the scope of our study, which focused specifically on assessing methodological characteristics of CPGs, particularly regarding their use of evidence-based components such as SRs and GRADE methodology. Future research could explore the concordance between the content of Peruvian CPGs and the country's epidemiological profile, which would provide valuable insights into the strategic focus and relevance of national guideline development. R4.8: Narrative synthesis could be strengthened with quantitative visualization A table or heatmap comparing GRADE components across institutions would enhance the clarity and accessibility of the findings, particularly for policymakers and non-specialist readers. Answer: Thank you for your suggestion. We agree that visual tools can help synthesize complex data. However, we opted to present our findings in detailed percentage-based tables (Tables 2 and 3), which we believe provide more precise and interpretable information, especially for readers who require exact data to inform policy or methodological decisions. A heatmap may obscure the magnitude of differences, particularly for components with low or moderate frequencies. Given the diversity of methodological practices across institutions, we considered that a tabular format would better support the clarity, transparency, and usability of the data. R4.9: Insufficient discussion of implications for end-user utility While the absence of Summary of Findings (SoF) tables and EtD frameworks is highlighted, the practical implications for clinicians or decision-makers are not fully elaborated. This connection should be strengthened. Answer: Thanks for your observation. To address this, we have added a sentence in the Discussion section: “The absence of SoF tables and EtD frameworks in a substantial proportion of CPGs may reduce their practical utility for clinicians and policymakers [20]. SoF tables synthesize the key findings in an accessible format, facilitating transparent and rapid interpretation of the certainty of evidence and magnitude of effects [30]. Likewise, EtD frameworks support decision-makers in adapting recommendations to local contexts by explicitly considering factors such as resource availability, feasibility, equity, and patient preferences [31]. Without these tools, recommendations may lack clarity, contextual relevance, or perceived credibility, potentially limiting their implementation and impact in real-world settings [31].” 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94. https://doi.org/10.1016/j.jclinepi.2010.04.026 30. Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol. 2013;66(2):158-72. https://doi.org/10.1016/j.jclinepi.2012.01.012 31. Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frame Submitted filename: Response_to_reviewers_auresp_3.docx 14 Dec 2025 Methodological characteristics of Peruvian clinical practice guidelines, 2018 - 2023: a scoping review PONE-D-24-51671R3 Dear Dr. Taype-Rondan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support . If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Saravana Kumar Academic Editor PLOS One Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes ********** Reviewer #2: This is my third time to review the paper. Overall, I think this paper is interesting and meet the requirement for publication. I still have a little bit humble advice to improve the paper: Consider some data visualization to make the paper more readable and attractive (for example, a heatmap for Table 3, a distribution graph for the level of care or sector of care). Insert Peru-specific data, or explicitly state that such data are unavailable, in Discussion or Limitations part. Just a single word should be enough. The third little comments is to make implications or policy tangible for clinicians. For example, give one brief example where missing EtD hampered implementation. This will make your article more meaningful. ********** what does this mean? ). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No ********** PONE-D-24-51671R3 PLOS One Dear Dr. Taype-Rondan, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Professor Saravana Kumar Academic Editor PLOS One